Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults
Latest Information Update: 07 Nov 2019
Price :
$35 *
At a glance
- Drugs XC-221 (Primary)
- Indications Influenza virus infections; Respiratory tract infections; Viral infections
- Focus Therapeutic Use
- Sponsors Pharmenterprises
- 14 Oct 2019 Status changed from recruiting to completed.
- 13 Mar 2018 New trial record